Chrs stock price forecast technical support near $1

Technical support near $1.75 has held firm, and CHRS stock price forecast incorporates potential rebound momentum from oversold conditions. Coherus is both a commercial and clinical-stage biopharma firm, with several approved biosimilar drugs on the market and multiple research tracks ongoing, ranging in stage from preclinical development to BLA submissions. The long-term goal of the company’s research program is to expand the range of cost-effective medicines and deliver significant savings to the U.S. healthcare system. Ahead of this earnings release , the estimate revisions trend for Coherus Oncology was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Institutional holdings have quietly increased, reinforcing a CHRS stock price forecast that anticipates sustained support above $2.